CorAssist Cardiovascular Ltd.

CorAssist Cardiovascular Ltd. is a clinical stage medical device company founded in 2003 in Israel, with a mission to develop innovative therapeutic products for treating Heart Failure with preserved Ejection Fraction (HFpEF). The company's flagship product, CORolla®, is a unique elastic self-expanding internal spring-like device implanted inside the left ventricle, aimed at improving cardiac diastolic function. This breakthrough technology offers significant potential in addressing a critical unmet need in the realm of cardiovascular health. Additionally, their first product, ImCardia®, is designed to enhance diastolic dynamics and filling performance with a straightforward off-pump procedure. In November 2018, CorAssist received a significant €71.43K grant investment from EASME - EU Executive Agency for SMEs, highlighting the recognition and support from prominent stakeholders in the European Union. The company's pioneering approach in combating HFpEF presents an exciting opportunity for investors seeking to engage with cutting-edge solutions in the Health Care sector. CorAssist's innovative technologies and strategic advancements position the company as a compelling investment prospect within the thriving landscape of medical device innovation.